Literature DB >> 23083022

Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.

Chi-Yung Shang1, Susan Shur-Fen Gau.   

Abstract

OBJECTIVE: Atomoxetine is efficacious in reducing symptoms of attention- deficit/hyperactivity disorder (ADHD), but its effect on visual memory and attention needs more investigation. This study aimed to assess the effect of atomoxetine on visual memory, attention, and school function in boys with ADHD in Taiwan.
METHOD: This was an open-label 12 week atomoxetine treatment trial among 30 drug-naíve boys with ADHD, aged 8-16 years. Before administration of atomoxetine, the participants were assessed using psychiatric interviews, the Wechsler Intelligence Scale for Children, 3rd edition (WISC-III), the school function of the Chinese version of the Social Adjustment Inventory for Children and Adolescents (SAICA), the Conners' Continuous Performance Test (CPT), and the tasks of the Cambridge Neuropsychological Test Automated Battery (CANTAB) involving visual memory and attention: Pattern Recognition Memory, Spatial Recognition Memory, and Reaction Time, which were reassessed at weeks 4 and 12.
RESULTS: Our results showed there was significant improvement in pattern recognition memory and spatial recognition memory as measured by the CANTAB tasks, sustained attention and response inhibition as measured by the CPT, and reaction time as measured by the CANTAB after treatment with atomoxetine for 4 weeks or 12 weeks. In addition, atomoxetine significantly enhanced school functioning in children with ADHD.
CONCLUSION: Our findings suggested that atomoxetine was associated with significant improvement in visual memory, attention, and school functioning in boys with ADHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23083022     DOI: 10.1089/cap.2011.0149

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  8 in total

1.  Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.

Authors:  Helen Fox; Mehmet Sofuoglu; Rajita Sinha
Journal:  J Psychopharmacol       Date:  2015-01-07       Impact factor: 4.153

2.  The use of reaction time distributions to study attention in male rats: the effects of atomoxetine and guanfacine.

Authors:  Zach V Redding; Pooja Chawla; Karen E Sabol
Journal:  Psychopharmacology (Berl)       Date:  2019-07-18       Impact factor: 4.530

Review 3.  The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.

Authors:  Helen Fox; Rajita Sinha
Journal:  Adv Pharmacol       Date:  2014

4.  Neural correlates of atomoxetine improving inhibitory control and visual processing in Drug-naïve adults with attention-deficit/hyperactivity disorder.

Authors:  Li-Ying Fan; Tai-Li Chou; Susan Shur-Fen Gau
Journal:  Hum Brain Mapp       Date:  2017-06-28       Impact factor: 5.038

5.  Influence of Disruptive Behavior Disorders on Academic Performance and School Functions of Youths with Attention-Deficit/Hyperactivity Disorder.

Authors:  Chao-Yu Liu; Wei-Lieh Huang; Wei-Chih Kao; Susan Shur-Fen Gau
Journal:  Child Psychiatry Hum Dev       Date:  2017-12

Review 6.  The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.

Authors:  Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

7.  Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.

Authors:  Kristi R Griffiths; John E Leikauf; Tracey W Tsang; Simon Clarke; Daniel F Hermens; Daryl Efron; Leanne M Williams; Michael R Kohn
Journal:  J Psychiatr Res       Date:  2018-03-27       Impact factor: 5.250

8.  Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate.

Authors:  David R Coghill; Tobias Banaschewski; Caleb Bliss; Brigitte Robertson; Alessandro Zuddas
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.